Insulin-Amylin Co-Formulation for Pump Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin therapies for diabetes, particularly rapid-acting insulin analogs, fail to optimally control post-prandial hyperglycemia due to glucagon production after meals, leading to inadequate glucose regulation and excessive insulin use, and existing formulations lack stability and compatibility for long-term use in insulin pumps.
Innovation Solution
A pharmaceutical composition of a rapid-acting insulin analog with A21 substitution, combined with a glucagon suppressor like pramlintide, formulated at a pH range of 3.0 to 4.4, which accelerates insulin absorption and maintains physical and chemical stability for at least two years at 2-8°C and two weeks at 30°C, ensuring compatibility with insulin pumps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If rapid-acting insulin analogs are used to control post-prandial glycemia, then the onset of action is faster compared to regular insulin, but glucagon production after meals is not suppressed leading to inadequate glucose regulation
Solution Approach 1:
The patent combines rapid-acting insulin analog (lispro) with a glucagon suppressor (pramlintide) into a single pharmaceutical composition. This merging allows simultaneous delivery of both agents with complementary mechanisms: insulin lowers blood glucose while pramlintide suppresses glucagon secretion, together providing superior post-prandial glycemic control compared to insulin alone
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing both insulin analog and glucagon suppressor at acidic pH (3.0-4.4). This composite composition leverages the synergistic effects of both components, where pramlintide's glucagon-suppressing property enhances insulin's glucose-lowering effect, addressing the limitation of insulin monotherapy
2Reliability
If insulin and glucagon suppressor are combined in a single composition, then the control of post-prandial glycemia is improved, but the formulation stability and compatibility for long-term use in insulin pumps is challenged
Solution Approach 1:
The patent utilizes acidic pH (3.0-4.4) as a key parameter to stabilize both insulin analog and glucagon suppressor in the same formulation. This pH condition prevents precipitation of insulin while maintaining pramlintide stability, enabling long-term storage stability (2 years at 2-8°C) and compatibility with insulin pump systems
Solution Approach 2:
The acidic pH environment acts as an intermediary condition that mediates between the conflicting stability requirements of insulin and pramlintide. This pH range serves as a compromise that prevents insulin hexamer formation and aggregation while maintaining pramlintide solubility and activity, enabling stable co-formulation
3Reliability
If regular insulin is administered 30 minutes before the meal, then the glycemia control is achieved, but the convenience and flexibility of administration is reduced
Solution Approach 1:
The rapid-acting insulin analog lispro is designed with preliminary structural modifications (proline-to-lysine substitution at B29 position) that pre-configure the molecule for faster absorption. This preliminary structural action enables the insulin to be administered at mealtime rather than 30 minutes before, improving convenience while maintaining effective glycemic control
Data Source
AI summary
A composition in the form of an injectable aqueous solution, the pH of which is from 3.0 to 4.4, in particular from 3.6 to 4.4, including at least a rapid-acting insulin analog and at least one glucagon suppressor with prandial action. The glucagon suppressor with prandial action is selected from the group consisting of an amylin analog or an amylin receptor agonist or a GLP-1 analog or a GLP-1 receptor agonist (GLP-1 RA). The glucagon suppressor with prandial action is an amylin analog or an amylin receptor agonist. The glucagon suppressor peptide with prandial action is pramlintide.